Abstract 379P
Background
Pancreatic cancer is associated with poor prognosis. Several potential biomarkers are present for predicting prognosis however predicting the response to chemotherapy is challenging. Lymphocyte-to-monocyte ratio (LMR) has emerged as a promising prognostic marker. Incorporating LMR into clinical decision-making can help identify patients who may require more aggressive treatment or closer monitoring. We aim by this work to assess the influence of LMR as a cheap available and reliable biomarker on the outcome of patients receiving chemotherapy for unresectable cases in order to predict the poor outcome and select the optimal therapeutic strategies.
Methods
This study included 50 patients with unresectable pancreatic cancer presented to Alexandria Clinical Oncology Department (ACOD) from January 2020 to the December 2022 and treated with chemotherapy. The files of these patients were reviewed, the complete blood count (CBC) prior to and one month after the beginning of chemotherapy were retrieved. Analysis done by IBM SPSS software version 20.0. Significance was judged at the 5% level.
Results
The mean age was 58.14. No statistically significant difference observed in the mean lymphocyte and monocyte counts before and after one month of chemotherapy. 16% of the patients showed disease progression, 50% had complete response. The mean overall survival (OS) and progression free survival (PFS) were 17.24 and 19.74 months respectively. Patients with high LMR1 had a significantly higher mean OS and PFS (24 months) compared to those with low LMR1 (10.39 & 10.66 months). There was a statistically significant difference in mean OS & PFS between patients with low LMR2 and those with high LMR2. Complete and partial responses were higher in patients with high LMR2, while disease progression was higher in those with low LMR2, and this difference was statistically significant.
Conclusions
our study findings suggested that elevated pretreatment LMR is associated with better OS ,PFS as well as better response to chemotherapy in patients with pancreatic cancer. In addition, we found that pretreatment LMR may act as a novel indicator for the prognosis of pancreatic cancer patients.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.